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Background
Historically, the United States has resettled more than 50,000 
refugees per year, half of whom are under 18 [1-3].  Although 
this number has decreased significantly over the past two years, 
refugees continue to arrive from either their country of origin or 
a refugee camp in another country, typically in the same region 
of the world as their country of origin.  The state of Kentucky 
has resettled over 15,000 refugees since 2012 [1].  The most 
common countries of origin for refugees entering Kentucky 
over the last several years have been Cuba, Iraq, Somalia, 
Burma/Myanmar, Democratic Republic of Congo, and Bhutan-
Nepal [1].   Refugee populations are a vulnerable and medically 
disenfranchised group in both their countries of origin and 
resettlement.   As no centralized database for the collection and 
storage of refugee health data exists, individual states are tasked 
with the development and maintenance of refugee health data at 
the time of resettlement.  The Kentucky Office for Refugees and 
the University of Louisville Global Health Center work together 
to perform the domestic health screenings of Kentucky’s newly 
arrived refugees.  
The Centers for Disease Control and Prevention (CDC) 
oversees mandated health screenings in accordance with the 
Refugee Act of 1980 [4].   At least 1/3 of the world’s population 
is infected with parasites, making this a common condition 
in refugees resettled in the United States (US) [1, 3, 5, 6]. 
These infections may be subclinical and can be associated with 
substantial morbidity, including anemia, malnutrition, small 
bowel obstruction, growth restriction, periportal hypertension, 
hyperinfection syndrome and possible cognitive impairment in 
children if not treated [2, 6].  In May 1999, the CDC initiated 
pre-departure treatment programs for intestinal parasites, 
which began with a single dose of Albendazole within 3 days of 
departure to the US for all non-pregnant refugees over the age of 
2 [4, 5, 7].  In addition to Albendazole, the guidelines expanded 
in 2005 to include treatment for Strongyloidiasis (Ivermectin) 
in refugees from Asia, the Middle East, and non-Loa Loa 
endemic African countries and treatment for Schistosomiasis 
(Praziquantel) in refugees from sub-Saharan Africa [4, 5, 7, 8]. 
Children are a special population because no presumptive anti-
helminth treatment is recommended in those under 12 months 
of age and there are limitations to the use of Praziquantel and 
Ivermectin [2, 4, 9]. It is expected that pediatric refugees who 
arrive from a refugee camp would be more likely to receive 
appropriate pre-departure treatment because they are in a more 
controlled setting and as a result of the treatment, less likely to 
have intestinal parasites on their intake examinations. However, 
it is unclear and not previously documented if the suboptimal 
living conditions with close exposure to others from various 
regions change the intestinal parasite diaspora in this group [5]. 
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The objectives of this study were to characterize and compare 
the intestinal parasite infection profiles and pre-departure 
treatment of Kentucky pediatric refugees who arrived from 
traditional refugee camps with those who did not arrive through 
a refugee camp. The authors will also describe the compliance of 
pre-departure treatment to the CDC recommendations in this 
population.
Methods
In 2012, the Kentucky Office of Refugees, in collaboration with 
the University of Louisville Global Health Center, created a 
secure database which stored the data from all domestic health 
screenings of refugees entering Kentucky.  This database was kept 
in the REDCap platform (Developed at Vanderbilt University 
Institute for Clinical and Translational Research; Nashville, TN) 
and maintained by the University of Louisville Global Health 
Center.  Information pertaining to refugee care, specifically pre-
departure anti-helminth treatment, prior to entry into the US 
is also maintained within the database and is provided directly 
from the CDC’s Electronic Disease Network (EDN), which is a 
centralized electronic reporting system that notifies US state 
and local health departments as well as screening clinics of the 
arrival of refugees and immigrants with medical conditions 
requiring follow-up [15].  The investigators received permission 
from the University of Louisville Institutional Review Board 
(IRB) to review charts from the REDCap database for this study.
This is a retrospective, descriptive study of patient charts in 
the REDCap database from September 1, 2012 to September 
1, 2017.  All refugees < 18 years of age and not pregnant at the 
time of treatment were included in the analysis of the parasite 
profiles. Refugees without any documentation pertaining to 
their previous residence within or outside of traditional refugee 
camps were excluded from all analyses. In addition, refugees 
with known cysticercosis or an unexplained seizure disorder 
were excluded through the CDC’s Albendazole-treatment 
protocol because of the risk of adverse neurological effects from 
a cytocidal agent[4]. 
The patient charts were grouped based on the region of the world 
from which they originated which was documented in their 
immigration/refugee records. The CDC groups the countries 
of origin into 3 major regions based on previous epidemiologic 
information about the endemic intestinal parasites: Middle 
East, Asia, North Africa, Latin America, and the Caribbean 
(Region 1); Central and Southern African countries not endemic 
for Loa Loa (Region 2); Central and Southern African countries 
endemic for Loa Loa (Region 3)[4]. The recommendation for 
pre-departure treatment for refugees from Region 1 is single 
dose Albendazole and Ivermectin; Region 2 is single dose 
Albendazole, Ivermectin, Praziquantel; Region 3 is single 
dose Albendazole and Praziquantel [4]. Additionally, the 
recommendations consider the safety profile of each medication, 
particularly in children. Praziquantel is not recommended for 
children < 4 years of age while Ivermectin is not recommended 
for children < 15 kilograms(kg). The CDC does not recommend 
presumptive therapy in children < 12 months of age [2, 4].
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Figure 1 Overall review of the Kentucky refugee data included in the 
data analysis
Table 1 Country of Origin and refugee camp status in Kentucky pediatric 
refugees










































Refugee camp (N=694) No refugee camp (N=959) All refugees (N=1653)
treated and parasite positive treated and parasite negative



















Dem. Rep. of the Congo 628 239 867 
Somalia 409 143 552 
Myanmar 158 218 376 
Iraq 5 371 376 
Bhutan 274 1 275 
Syria 20 234 254 
Cuba 0 242 242 
Afghanistan 5 70 75 
Sudan 18 20 38 
Burundi 28 3 31 
Pakistan 0 25 25 
Eritrea 4 18 22 
Rwanda 11 4 15 
Ethiopia 3 4 7 
Sri Lanka 0 7 7 
Ukraine 0 7 7 
Kenya 4 0 4 
Ivory Coast 0 4 4 
Saudi Arabia 0 4 4 
Tanzania 3 0 3 
Lebanon 0 3 3 
Thailand 2 0 2 
Kuwait 0 2 2 
Central African Republic 1 0 1 
Ghana 1 0 1 
Nepal 1 0 1 
North Korea 1 0 1 
Turkey 1 0 1 
Angola 0 1 1 
Iran 0 1 1 
Jordan 0 1 1 
Total 1577 1622 3199 
The results of stool cultures were compared between those who 
arrived through a refugee camp and those who did not. The 3 
regional subgroups were used evaluate potential trends in 
parasite diaspora based on region and refugee camp status. The 
records were reviewed to determine if the included pediatric 
refugees received appropriate pre-departure treatment for 
intestinal parasites as outlined by the CDC.  Children < 4 
years of age were excluded from this analysis because of the 
anti-helminth restrictions in the younger and smaller weight 
individuals.  The stool pathology was described for those who 
received appropriate pre-departure treatment and those who 
did not. It was further described within the 3 regional groups 
and refugee camp status.
A sensitivity analysis was conducted using the refugees < 4 years 
of age and < 12 months of age to determine the appropriateness 
of treatment and determine if they had different intestinal 
parasite profiles compared to those 4 years of age and older. The 
descriptive analysis of all the data was performed using IBM 
SPSS version 21.
Results 
There were 3,584 pediatric refugee charts reviewed from 
9/1/2012 to 9/1/2017. 385 were excluded because the records 
were missing information about refugee camp stay prior to 
immigration into Kentucky, resulting in 3,199 pediatric refugee 
records (Figure 1). There were 686 (21.4%) pediatric refugees 
< 4 years of age and 57 (1.8%) < 12 months of age. Kentucky 
pediatric refugees most commonly came from The Democratic 
Republic of the Congo (Table 1).  
Upon arrival, there were 1,653 children who had stool studies 
results (Figure 2). There were 680 children that had abnormal 
stool studies and 426 (62.6%) received pre-departure therapy 
prior to arrival in the US.  In children who did not spend 
any time in a camp and had stool studies, 326 (33.9%) had 
intestinal parasites in their stool. In children who spent time in 
refugee camps and were tested, 354 (51%) were found to have 
parasites in their stool (Figure 2). In children who arrived to 
Kentucky from refugee camps and did not receive pre-departure 
treatment, the incidence of intestinal parasites was 71 out of 165 
(43%).
Overall, pre-departure anti-helminth therapy in refugees > 4 
years of age was appropriate based on CDC recommendations 
64.7% of the time. There were only 6 total cases of soil helminths, 
1 case of Strongyloides and no cases of Schistosomiasis. The 
most common parasites found in refugee children from all 
three regions were Blastocystis and Giardia (Table 2). The 
pediatric refugees from this Region 1 were treated based on CDC 
guidelines 83% of the time (Table 3).  There were 75 patients 
who arrived from Afghanistan. None of these patients received 
presumptive treatment regardless of refugee camp status and 
the most common organisms identified were also Giardia (18%) 
and Blastocystis (18%). Ascaris was present in 3% of the Afghani 
pediatric refugees. 
The pediatric refugees from Region 2 had a 79.8% compliance 
rate with CDC guidelines while the pediatric refugees 
from Region 3 had 30.2% compliance (Table 3). The CDC 
recommends that these individuals from Region 3 should have 
Ivermectin added based on the results of stool studies. However, 
if children who received all three as presumptive treatment 
were included in the “appropriate treatment” category, then 
compliance would be 85.5% for region 3 and 83.1% for all 
pediatric Kentucky refugees.
These results were further analyzed and grouped into children 
who were previously in a refugee camp and those who were not. 
Overall, in pediatric refugees previously in a refugee camp, they 
received appropriate presumptive intestinal parasite treatment 
61.7% of the time (Table 3).  The most common parasites 
found children previously in refugee camps from each of the 
three regions were Blastocystosis and Giardia (Figure 3). 
Based on the CDC recommendations by region, the children in 
Region 1 had 86.7% compliance, Region 2, 85.4% compliance, 
and Region 3, 22.5% compliance (Table 3).  If children in 
Region 3 who received all three medications were included in 
the “appropriate treatment” category, then compliance would 
be 88.4% for Region 3 and 86.9% for all pediatric Kentucky 
refugees who were previously in refugee camps. 
Overall, in pediatric refugees not previously in a refugee camp, 
they received appropriate presumptive therapy 69.8% of the 
time (Table 3). The most common parasites found in refugee 
children not previously in camps from each of the three regions 
were Blastocystosis and Giardia (Figure 3). Based on the CDC 
recommendations by region, the children in Region 1 had 80% 
compliance, Region 2, 56.4% compliance, and Region 3, 50.3% 
compliance (Table 3). If children in Region 3 who received all 
three medications were included in the “appropriate treatment” 
category, then compliance would be 78.3% for Region 3 
and 76.7% for all pediatric Kentucky refugees who were not 
previously in refugee camps. 
3
Table 2 Types of parasites detected in the stool culture results of 
pediatric refugees from the different world regions defined by the CDC
 
  
Stool culture  results Region 1  N (%) Region 2 N (%) Region 3 N (%) 
Blastocystis 152 (49.8) 78 (44.1) 117 (59.1) 
Giardia 55 (18) 44 (24.9) 27 (13.6) 
Giardia, Blastocystis 17 (5.6) 24 (13.6) 27 (13.6) 
Other nonpathogenic parasites 17 (5.6) 15 (8.5) 13 (6.6) 
Dientamoeba and Blastocystis 18 (5.9) 3 (1.7) 4 (2) 
Dientamoeba 15 (4.9) 3 (1.7) 0 
Entamoeba histolytica 7 (2.3) 0 6 (3) 
Entamoeba histolytica, Blastocystis 8 (2.6) 0 1 (0.5) 
Hymenolepis, Blastocystis 3 (1) 3 (1.7) 0 
Dientamoeba, Giardia, Blastocystis 3 (1) 1 (0.6) 1 (0.5) 
Entamoeba histolytica, Giardia 3 (1) 0 0 
Dientamoeba, Giardia 1 (0.3) 1 (0.6) 0 
Entamoeba histolytica, Dientamoeba 1 (0.3) 0 0 
Trichuris, Dientamoeba 1 (0.3) 0 0 
Strongyloides 1 (0.3) 0 0 
Giardia, Blastocystis, Hymenolepis 1 (0.3) 0 0 
Dientamoeba, Hymenolepis, Blastocystis 1 (0.3) 0 0 
Ascaris, Giardia 1 (0.3) 0 0 
Hymenolepis 0 1 (0.6) 0 
Tapeworm, Blastocystis 0 1 (0.6) 0 
Trichuris 0 0 1 (0.5) 
Giardia, Trichuris, Blastocystis 0 1 (0.6) 1 (0.5) 
Trichuris, Blastocystis 0 1(0.6) 0 
Giardia, Tapeworm, Blastocystis 0 1(0.6) 0 
Total 305 177 198 
Table 3 Kentucky refugee children who received appropriate anti-
helminth treatment based on the CDC recommendations prior to arrival 
in the United States
 
 
Refugee Population Refugee camp 
No refugee 
camp Total 
Region 1. Asia, Middle East, North 
Africa, Latin American, & Caribbean 86.7% 80% 83% 
Region 2. Sub-Saharan Africa,  
non-Loa loa-endemic area 85.4% 56.4% 79.8% 
Region 3. Sub-Saharan Africa,  
Loa loa– endemic area 22.5% 50.3% 30.2% 











































































Region 3- no refugee camp
Region 1 - no refugee camp Region 1 - refugee camp
Region 3 - no refugee camp Region 3 - refugee camp
Region 2 - no refugee camp Region 2 - refugee camp
Figure 3 The most common intestinal parasites by region and history of refugee camp exposure
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An analysis was conducted looking at pediatric refugees < 
4 years of age and < 12 months to determine if they were 
inappropriately receiving anti-helminth treatment and if their 
stool culture results were different from the remainder of the 
charts reviewed. In children < 4 years, pre-departure treatment 
was given in 416 patients. There were 37 (8.8%) patients who 
received Praziquantel, which is not approved in this group. 32 
of these children arrived through a refugee camp. There were 
65 refugees < 4 years who were given Ivermectin. 47 (72.3%) 
of these patients were under 15 kg and therefore should not 
have received it. Seven of the children < 15 kg who received 
Ivermectin arrived through a refugee camp.  In summary, there 
were 20.1% of children who received Praziquantel or Ivermectin 
despite contraindications based on age and weight. 46.4% of 
these children arrived through a refugee camp.
There were 354 refugees < 4 years who were tested for intestinal 
parasites. 92 had positive stool studies on evaluation, 51 of 
which received pre-departure treatment. The most common 
organisms were Giardia and Blastocystis and there were no 
cases of soil helminths, Schistosomiasis, or Strongyloides.
There were 11 (17.4%) refugee children < 12 months of age 
who received pre-departure treatment for intestinal parasites 
despite the CDC recommendations. Forty (of the total 63) 
children < 12 months of age were tested for intestinal parasites 
and 3 had positive stool cultures, which resulted Giardia and/
or Blastocystis. None of the 3 refugee children < 12 months 
of age who had positive stool cultures received pre-departure 
treatment.
Discussion
The current CDC guidelines for pre-departure treatment of 
intestinal parasites in refugees were designed to specifically 
address infections with soil transmitted helminths, 
Strongyloides, and Schistosomiases.  This study supports the 
findings of other numerous studies performed on refugees 
resettling in other US and Western cities which demonstrate 
a low incidence of infection with these parasites while also 
demonstrating the persistent burden of protozoal infections, 
specifically Giardia and Blastocystis [4, 5, 10, 11]. 
The distinction between prior living environments (refugee 
camp vs none) has been used to explain differences in health 
profiles of newly arriving refugee children, however differences 
in intestinal parasite burden and pre-treatment medications 
has not been evaluated prior to this study [12].  This study 
demonstrated similar stool parasite profiles in pediatric 
refugees regardless of prior encampment status and country 
of origin; however, those arriving directly from refugee camps 
presented with higher rates of positive stool results.  This is 
likely attributed to irregular access to preventive health services, 
insufficient sanitation facilities and hygiene practices, and 
higher likelihood of transmission rates of communicable illness 
particularly among children living in poor housing and close 
quarters conditions [12].
Children who arrived through refugee camps had a lower 
compliance with CDC recommendations for pre-departure 
therapy compared to those who did not arrive through refugee 
camps; however, this appears to be skewed by Region 3. 
Refugees arriving through camps from Regions 1 and 2 had a 
high compliance with CDC recommendations with appropriate 
pre-departure treatment rates of 86.7% and 85.4% respectively, 
while Region 3 compliance was low. The guidelines recommend 
refugees from Region 3 receive Albendazole and Praziquantel 
but many of the Kentucky pediatric refugees received triple-
therapy with Albendazole, Praziquantel, and Ivermectin [4]. 
While overtreatment in this group should not increase parasite 
burden as identified by stool studies, it unnecessarily increases 
the risk of encephalopathy associated with a high load of dying 
microfilaria in an established Loa Loa endemic region [4, 9]. 
Therefore, the CDC guidelines should be more closely adhered 
to in this group of individuals as originally designed. Based 
on these findings, education initiatives focused on health care 
workers working in refugee camps located in countries endemic 
for Loa Loa are recommended to improve the adherence to the 
CDC guidelines for pre-departure parasite treatment.
This study additionally found that there was inappropriate pre-
departure treatment of young children. 86% of the children < 
4 years of age who received Praziquantel and 14.9% of children 
< 15 kg who received Ivermectin arrived through a refugee 
camp. The American Academy of Pediatrics warns against the 
use of Ivermectin in children under 2 years of age and under 
15 kg because they have a less developed blood brain barrier 
and therefore have a higher risk of central nervous system 
side effects, namely encephalopathy [9]. The culture results 
in children < 4 and those < 12 months are similar to children 
in the overall study population and didn’t show an increase 
in soil helminths, Strongyloides, or Schistosomiasis in the 
children who did not receive pre-departure therapy.  These 
findings further support the need to improve adherence to the 
guidelines set forth by the CDC, through awareness, education, 
and treatment coordination among refugee camp healthcare 
workers, since presumptive therapy will not provide any added 
benefit in these populations but will increase the number of 
possible adverse effects. 
This study showed Giardia and Blastocystis as the major stool 
pathogens in Kentucky pediatric refugees. It has been debated 
whether Blastocystis is a pathogenic organism; however, some 
suggest to treat if a patient is symptomatic and has no other 
identifiable organism in the stool [13].  Giardia can cause 
diarrhea, malaise, abdominal cramping, nausea, weight loss, 
and failure to thrive [9]. At this time, treatment of symptomatic 
individuals is recommended to prevent infection and hasten the 
resolution of symptoms; however, the illness is typically self-
limiting. Currently, the stool of pediatric Kentucky refugees 
is only tested if symptomatic and therefore would warrant 
treatment. There are many individuals who are asymptomatic 
and have Giardia in their stool. These patients only require 
treatment if there is an increased risk of transmission to others 
[9, 14]. This includes children who attend daycare/school, live 
at home with an immunocompromised individual, live at home 
with a pregnant woman, or handle food [9].  Unfortunately, 
many of the Kentucky pediatric refugees will fall into this 
group and require treatment even if they are asymptomatic. 
Albendazole daily for 5 days or Metronidazole 3 times daily 
for five days can be used to treat Giardia infections in any age 
individual [14].  Although Albendazole is more convenient at 
once daily, Metronidazole is a more cost-effective treatment 
in the US. In addition, Metronidazole would be an appropriate 
treatment for Blastocystis in the setting of symptomatic illness 
and absence of other causative organisms [13].
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The authors recommend the initiation of treatment with 
Metronidazole promptly in symptomatic refugee children who 
have received appropriate pre-departure treatment.  Screening 
studies can take several days to weeks and this would provide 
antimicrobial coverage for Giardia and Blastocystis and 
therefore, prevent the spread of infection in a population where 
follow up and language barriers can challenge the provision of 
appropriate treatment and healthcare.
The data for this study were obtained through a database review, 
therefore a limitation of the study is incorrectly inputted data 
into REDCap. However, a large number of charts were reviewed 
to offset any effect of random human error and all data gathered 
from pre-departure health assessments were provided directly 
from the CDC’s EDN, which is unlikely to have incorrectly 
inputted data [15]. Another limitation is the lack of follow up 
information for those patients who had positive stool results. 
Because the database captured intake data, it does not have 
information about the treatment and follow up in those children 
with positive stool studies.  Additionally, stool ova and parasite 
testing have low sensitivity for many intestinal parasites, 
especially if only one or two samples were submitted, therefore 
our measurement of parasite burden likely underestimates the 
true prevalence of intestinal parasites within our clinical samples. 
Lastly, refugees provided stool studies if they were symptomatic 
upon arrival or if they presented to their initial screening visits 
with incomplete records of pre-departure treatment.  Therefore, 
we cannot evaluate the positive predictive value of stool testing 
in our study population as we cannot differentiate those who 
underwent stool studies due to symptoms and those who did 
not present with adequate information to their initial screening 
visit.
In conclusion, there is high compliance to the CDC 
recommendations for presumptive treatment of intestinal 
parasites in Kentucky pediatric refugees from Regions 1 and 2. 
Refugees from region 3 are inappropriately given Ivermectin 
which can cause encephalopathy in patients in this high risk 
group and interventions should be focused on improving 
compliance with CDC recommendations in this group and in 
young children (< 4 years).   Early initiation of Metronidazole in 
symptomatic pediatric refugees should be considered to prevent 
the spread of protozoal infection upon resettlement. 
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